Coriolis Pharma to Expand German HQ
Project is expected to grow CRDO’s capacity by over 150,000 square feet
Coriolis Pharma, a globally operating contract research and development organization (CRDO), is growing its current headquarters by establishing a new campus.
Located in the heart of Martinsried, which is a section of Planegg in the district of Munich, the new Coriolis campus is expected to double its overall capacity to 14,000 square meters (approximately 150,695 square feet). It will include two new buildings (Fraunhoferstrasse 14 and F14b), the current headquarters (F18b), and two additional locations (F8 and F11a). The new campus with interconnected buildings will provide additional lab and office space, allowing for future growth opportunities. The first building will be operational in early 2024, while the completion of the entire campus is planned for 2025.
The construction product will consist of two phases. In the first phase, a modern lab infrastructure, consisting of multipurpose facilities and office spaces will be built. Phase 2 includes a new facility with an employee restaurant, among other features.
Layout of HQ's future campus
